Add preferred source
Takara Holdings on the 23rd released its April-June 2026 earnings, which had been delayed amid questions over the accounting treatment at its U.S. subsidiary Takara Bio USA. An investigation involving outside lawyers found no intentional accounting fraud and concluded no prior-year restatement was necessary. April-June sales came to ¥103.2 billion (approximately $657.9 million), up 10.6% year on year, while net profit fell 12.4% to ¥3.6 billion (approximately $22.9 million). At the same time, the company raised its full April-September net profit forecast to ¥11.6 billion (approximately $73.9 million), 2.1 times its previous projection of ¥5.9 billion (approximately $37.6 million). Top shareholder ValueAct Capital has requested an extraordinary general meeting of shareholders seeking the dismissal of three outside directors, and Takara Holdings said it will review the request and decide how to respond.
Key Elements
Takara Holdings (HD), based in Kyoto, on the 23rd released its consolidated earnings for the April-June 2026 quarter about two months late. The company had held off on the announcement since August after its auditing firm flagged unclear points in the accounting treatment at Takara Bio USA, the U.S. subsidiary that runs its biotech business. An investigation involving outside lawyers found only accounting errors, with no intentional fraud confirmed. The impact on results was minor, and the company concluded that no restatement of prior-year earnings was needed.
Sales for the April-June quarter announced the same day rose 10.6% year on year to ¥103.2 billion (approximately $657.9 million), operating profit fell 14.7% to ¥2.9 billion (approximately $18.5 million), and net profit fell 12.4% to ¥3.6 billion (approximately $22.9 million). Profit was weighed down by ¥1.6 billion (approximately $10.2 million) in business restructuring costs booked as an extraordinary loss, including enhanced retirement benefits tied to Takara Bio’s voluntary early-retirement program.
Takara Holdings also revised up its consolidated forecast for the full April-September period. Net profit is expected to come in at ¥11.6 billion (approximately $73.9 million), 2.1 times the year-earlier level, a sharp upgrade from its previous projection of ¥5.9 billion (approximately $37.6 million), which had implied a 4% increase. Price revisions in its overseas business wholesaling Japanese food ingredients contributed, while U.S. reciprocal tariff refunds and currency movements also lifted profit. Sales are expected to rise 13% to ¥210.8 billion (approximately $1.3 billion), ¥5.8 billion (approximately $37.0 million) above the previous forecast. Both overseas alcoholic beverages and the overseas Japanese food-ingredient wholesale business exceeded expectations.
| Item | April-June 2026 Actual | Year-on-Year |
|---|---|---|
| Sales | ¥103.2 billion | +10.6% |
| Operating profit | ¥2.9 billion | -14.7% |
| Net profit | ¥3.6 billion | -12.4% |
| Item | April-September 2026 Forecast | Previous Forecast |
|---|---|---|
| Sales | ¥210.8 billion (+13%) | ¥205 billion |
| Net profit | ¥11.6 billion (2.1x) | ¥5.9 billion |
Note: Year-on-year comparisons are based on each company’s disclosures. April-September net profit represents a substantial upward revision from the previous forecast.
At subsidiary Takara Bio, the reagent business is underperforming expectations. Selling, general and administrative expenses are expected to decrease, narrowing the loss, due to a review of contingent consideration tied to product development progress that was agreed when the company acquired a U.S. startup developing reagents for genetic analysis.
Meanwhile, tension with shareholders over management continues. ValueAct Capital, an investment fund that is Takara Holdings’ top shareholder with roughly 20% of its shares, said on the 22nd that it had requested the convening of an extraordinary general meeting of shareholders. Citing missed management targets and weak profit margins, it argued that the board’s oversight function is not working and is seeking the dismissal of three outside directors and the appointment of three new directors.
At the earnings briefing on the 23rd, Masakazu Usami, head of Takara Holdings’ public relations and investor relations department, said of the delay in the earnings announcement: “We apologize to all concerned parties for the inconvenience and concern we have caused.” On the shareholder proposal, he said: “We take their views seriously. We will carefully examine the details and decide how to respond.” The company said it does not believe it has refused dialogue, and will decide its policy at a board meeting after reviewing the details of the request.
With the accounting questions resolved, investor attention is shifting to the earnings upgrade and the battle with the activist shareholder. While improved profitability in overseas operations drove the sharp upward revision to the full-period forecast, structural reform at Takara Bio and the response to the shareholder proposal remain management challenges ahead. Whether the extraordinary general meeting is held and how the proposals fare will likely shape the market’s assessment of the company’s governance.
